iBio to Participate in the JMP Securities Hematology and Oncology Summit

BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its Chief Scientific Officer, Martin Brenner, DVM, Ph.D., will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 7, 2022 at 1:20 p.m. Eastern Time.

The fireside chat will be broadcast live and archived on the Company's website at www.ibioinc.com under "News & Events" in the Investors section.

About iBio, Inc.

iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets. For more information, visit www.ibioinc.com.

Contact:

Stephen KilmeriBio, Inc.Investor Relations(646) 274-3580[email protected]

You May Also Be Interested In

• Crypto News: Remittix Announces Official Listing Date as Solana Price Prediction Targets $1,000
• Apollo Group TV Updates Official Website Information for Easier Access and User Guidance
• 2026 Global Open-source AI Challenge Grand Finals and Awards Ceremony Held in Hangzhou